Fracture Incidence Rates in Persons with Rheumatoid Arthritis by Disease Activity Level
Abstract format and assignment number: Oral presentation 1748
Presenting author: R. Elam (United States)
Date: Sunday, 17th November 2024
In this study, higher fracture incidence rates (IRs) were found in individuals with rheumatoid arthritis (RA) compared to those without, especially in those with higher disease activity. A retrospective cohort study (2016-2018) using RISE data linked to Medicare claims revealed that RA patients with disease activity above remission had higher rates of hip fractures and major osteoporotic fractures (MOF). This underscores the need for bone health monitoring in RA patients, particularly those with high disease activity.
What Are the Benefits of Treating Rheumatoid Arthritis Patients to Remission After Achieving Low Disease Activity in Clinical Practice?
Abstract format and assignment number: Oral presentation 1743
Presenting author: M. Weinblatt (United States)
Date: Sunday, 17th November 2024
This study from the BRASS registry assessed the incremental benefit of achieving remission in rheumatoid arthritis (RA) patients initially at low disease activity (LDA). Patients with CDAI ≤2.8 (remission) showed better functional outcomes and reduced durable medical equipment (DME) use compared to those with CDAI between 6 and 10. Achieving remission led to significant improvements in MDHAQ function scores and reduced DME use. New treatments targeting remission may reduce RA-related disability and healthcare costs.
Disease-associated Central Nervous System Activation Predicts Good Clinical Response to Tumor Necrosis Factor Inhibition in Rheumatoid Arthritis Patients – “The PreCePRA Study”
Abstract format and assignment number: Oral presentation 0871
Presenting author: J. Rech (Germany)
Date: Saturday, 16th November 2024
This study investigates whether high central nervous system (CNS) activation, measured through functional MRI (fMRI), predicts better clinical responses to TNF inhibitors (TNFi) in rheumatoid arthritis (RA). Patients were stratified based on fMRI voxel size and randomized to receive certolizumab-pegol (CZP) or placebo. Results showed that patients with high CNS activation (HV-CZP) achieved significantly better outcomes, particularly in patient-reported measures, compared to the placebo group, suggesting that CNS activation can predict TNFi response in RA.
The Impact of Body Mass Index on Cardiovascular Risk in Rheumatoid Arthritis Varies Across Anticitrullinated Protein Antibody Status and Biologic Use
Abstract format and assignment number: Oral presentation 0870
Presenting author: G. Karpouzas (United States)
Date: Saturday, 16th November 2024
This study explored how BMI influences cardiovascular risk in rheumatoid arthritis (RA) patients, factoring in ACPA status and bDMARD use. For ACPA-positive patients, higher BMI correlated with increased major adverse cardiovascular events (MACE). In ACPA-negative patients, BMI was inversely linked to MACE risk, but only in bDMARD users. The results highlight complex interactions, showing that BMI’s impact on cardiovascular outcomes varies based on disease markers and treatment.
Disease Activity Is Strongly Associated with RA-related Lung Disease and Interstitial Lung Disease in Early RA: Results from a Multicenter, Prospective Cohort Study
Abstract format and assignment number: Oral presentation 0802
Presenting author: G. McDermott (United States)
Date: Saturday, 16th November 2024
In this prospective multicenter study of early RA, 16% of patients developed RA-related lung diseases (ILD, bronchiectasis, emphysema). Active RA, male sex, and older age were significant predictors of lung disease, with moderate/high disease activity strongly linked to increased odds of ILD. The findings suggest that managing disease activity early in RA may reduce the risk of developing lung diseases, highlighting the importance of early diagnosis and effective treatment to prevent both articular and extra-articular complications.
Roba Ghossan
Roba is a rheumatologist at the Department of Rheumatology of Cochin Hospital APHP in Paris, France. Her main clinical and research interests include Inflammatory Rheumatic Diseases, MSK Ultrasound and Epidemiology.
Roba is a member of the French Society of Rheumatology and the society’s young rheumatologists section (REF). She is a member of the EMEUNET Social Media Sub-Committee.
E-mail: roba.ghossan@gmail.com